Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy

Purpose: To analyze preclinical bone regeneration studies employing mesenchymal stromal cell (MSC)- derived extracellular vesicles (EVs) and highlight any commonalities in EV biomarker expression, miRNA cargo(s) or pathway activation that will aid in understanding the underlying therapeutic mechanis...

Full description

Bibliographic Details
Main Authors: Vishnu Priya Murali, Christina A. Holmes
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Bone Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187221003491
id doaj-b1b9148a0b8647fbae27d99a8f099140
record_format Article
spelling doaj-b1b9148a0b8647fbae27d99a8f0991402021-06-03T04:57:29ZengElsevierBone Reports2352-18722021-06-0114101093Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapyVishnu Priya Murali0Christina A. Holmes1Department of Chemical and Biomedical Engineering, College of Engineering, Florida A&M University-Florida State University, 2525 Pottsdamer Street, Room A131, Tallahassee, FL 32310, USACorresponding author.; Department of Chemical and Biomedical Engineering, College of Engineering, Florida A&M University-Florida State University, 2525 Pottsdamer Street, Room A131, Tallahassee, FL 32310, USAPurpose: To analyze preclinical bone regeneration studies employing mesenchymal stromal cell (MSC)- derived extracellular vesicles (EVs) and highlight any commonalities in EV biomarker expression, miRNA cargo(s) or pathway activation that will aid in understanding the underlying therapeutic mechanisms. Methods: Articles employing EVs derived from either MSCs or MSC-like osteogenic stromal cells in preclinical bone regeneration studies are included in this review. Results: EVs derived from a variety of MSC types were able to successfully induce bone formation in preclinical models. Many studies failed to perform in-depth EV characterization. The studies with detailed EV characterization data report very different miRNA cargos, even in EVs isolated from the same species and cell types. Few preclinical studies have analyzed the underlying mechanisms of MSC-EV therapeutic action. Conclusion: There is a critical need for mechanistic preclinical studies with thorough EV characterization to determine the best therapeutic MSC-EV source for bone regeneration therapies. Issues including controlled EV delivery, large scale production, and proper storage also need to be addressed before EV-based bone regeneration therapies can be translated for clinical bone repair.http://www.sciencedirect.com/science/article/pii/S2352187221003491Extracellular vesiclesBone regenerationMesenchymal stromal cellsTissue engineeringmiRNABiomaterials
collection DOAJ
language English
format Article
sources DOAJ
author Vishnu Priya Murali
Christina A. Holmes
spellingShingle Vishnu Priya Murali
Christina A. Holmes
Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
Bone Reports
Extracellular vesicles
Bone regeneration
Mesenchymal stromal cells
Tissue engineering
miRNA
Biomaterials
author_facet Vishnu Priya Murali
Christina A. Holmes
author_sort Vishnu Priya Murali
title Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
title_short Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
title_full Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
title_fullStr Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
title_full_unstemmed Mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
title_sort mesenchymal stromal cell-derived extracellular vesicles for bone regeneration therapy
publisher Elsevier
series Bone Reports
issn 2352-1872
publishDate 2021-06-01
description Purpose: To analyze preclinical bone regeneration studies employing mesenchymal stromal cell (MSC)- derived extracellular vesicles (EVs) and highlight any commonalities in EV biomarker expression, miRNA cargo(s) or pathway activation that will aid in understanding the underlying therapeutic mechanisms. Methods: Articles employing EVs derived from either MSCs or MSC-like osteogenic stromal cells in preclinical bone regeneration studies are included in this review. Results: EVs derived from a variety of MSC types were able to successfully induce bone formation in preclinical models. Many studies failed to perform in-depth EV characterization. The studies with detailed EV characterization data report very different miRNA cargos, even in EVs isolated from the same species and cell types. Few preclinical studies have analyzed the underlying mechanisms of MSC-EV therapeutic action. Conclusion: There is a critical need for mechanistic preclinical studies with thorough EV characterization to determine the best therapeutic MSC-EV source for bone regeneration therapies. Issues including controlled EV delivery, large scale production, and proper storage also need to be addressed before EV-based bone regeneration therapies can be translated for clinical bone repair.
topic Extracellular vesicles
Bone regeneration
Mesenchymal stromal cells
Tissue engineering
miRNA
Biomaterials
url http://www.sciencedirect.com/science/article/pii/S2352187221003491
work_keys_str_mv AT vishnupriyamurali mesenchymalstromalcellderivedextracellularvesiclesforboneregenerationtherapy
AT christinaaholmes mesenchymalstromalcellderivedextracellularvesiclesforboneregenerationtherapy
_version_ 1721399740208250880